These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 14688750)

  • 1. Activated prothrombin complex concentrates and recombinant factor VIIa in the bleeding patient: are they appropriate and safe?
    Aledort LM
    J Thorac Cardiovasc Surg; 2003 Dec; 126(6):2112-3. PubMed ID: 14688750
    [No Abstract]   [Full Text] [Related]  

  • 2. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII.
    Bui JD; Despotis GD; Trulock EP; Patterson GA; Goodnough LT
    J Thorac Cardiovasc Surg; 2002 Oct; 124(4):852-4. PubMed ID: 12324751
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic decision-making in inhibitor patients.
    Allen G; Aledort L
    Am J Hematol; 2006 Jan; 81(1):71-2. PubMed ID: 16369965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis and recombinant factor VIIa.
    Hay CR
    J Thromb Haemost; 2004 Oct; 2(10):1698-9. PubMed ID: 15456477
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
    Barthels M
    Thromb Res; 1999 Aug; 95(4 Suppl 1):S31-8. PubMed ID: 10499907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recombinant factor VII in the treatment of acute hemorrhage due to esophageal varices].
    Jiménez-Sáenz M; Romero-Castro R
    Gastroenterol Hepatol; 2005; 28(6):333-6. PubMed ID: 15989815
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity--a rebuttal.
    Makris M; Van Veen JJ
    J Thromb Haemost; 2005 Apr; 3(4):818-9; author reply 819. PubMed ID: 15842387
    [No Abstract]   [Full Text] [Related]  

  • 8. Factor VII and activated factor VII content of prothrombin complex concentrates.
    Fiedler H
    Vox Sang; 1998; 75(1):72-3. PubMed ID: 9779562
    [No Abstract]   [Full Text] [Related]  

  • 9. Recombinant factor VIIa (Novoseven) and the safety of treatment.
    Roberts HR
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):48-50. PubMed ID: 11735111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of recombinant factor VIIa for bleeding in paediatric practice.
    Millar CG; Stringer MD; Sugarman I; Richards M
    Haemophilia; 2005 Mar; 11(2):171-4. PubMed ID: 15810920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant activated factor VII: a new weapon in the fight against hemorrhage.
    Branch DW; Rodgers GM
    Obstet Gynecol; 2003 Jun; 101(6):1155-6. PubMed ID: 12798515
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of prothrombin complex concentrates in anticoagulation.
    van Veen SQ; Strengers PF
    Am J Hematol; 2008 Apr; 83(4):344-5. PubMed ID: 18213649
    [No Abstract]   [Full Text] [Related]  

  • 13. A reappraisal of plasma, prothrombin complex concentrates, and recombinant factor VIIa in patient blood management.
    Goodnough LT
    Crit Care Clin; 2012 Jul; 28(3):413-26, vi-vii. PubMed ID: 22713615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of recombinant factor VIIa: a rebuttal.
    Teitel J; Poon MC
    J Thromb Haemost; 2004 Nov; 2(11):2078; author reply 2079. PubMed ID: 15550060
    [No Abstract]   [Full Text] [Related]  

  • 15. Off-label use of recombinant factor VIIA concentrates after cardiac surgery.
    Despotis G; Avidan M; Lublin DM
    Ann Thorac Surg; 2005 Jul; 80(1):3-5. PubMed ID: 15975330
    [No Abstract]   [Full Text] [Related]  

  • 16. Key concepts in the management of difficult hemorrhagic cases.
    MacLaren R
    Pharmacotherapy; 2007 Sep; 27(9 Pt 2):93S-102S. PubMed ID: 17723112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors.
    Hough RE; Hampton KK; Preston FE; Channer KS; West J; Makris M
    Br J Haematol; 2000 Dec; 111(3):974-9. PubMed ID: 11122162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current insights on the risk of thrombogenicity with off-label use of rFVlla.
    Key N
    Clin Adv Hematol Oncol; 2006 Jan; 4(1):34-5. PubMed ID: 16562367
    [No Abstract]   [Full Text] [Related]  

  • 19. Prophylactic treatment of a small child with severe factor VII deficiency using repeat dosing from a single vial of recombinant activated factor VII.
    Michaels LA; Philipp CS; Eisele J; Pappas H; Saidi P
    Pediatr Blood Cancer; 2007 Oct; 49(5):736-9. PubMed ID: 16317734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recombinant activated factor VII to control bleeding in cardiovascular surgery: need of efficacy and safety validation].
    Blanloeil Y; Rigal JC; Bastien O; Carteau JP; Toussaint-Hacquard M; Lecompte T
    Ann Fr Anesth Reanim; 2006 Jan; 25(1):2-5. PubMed ID: 16377121
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.